All In Biotech

Drug Trial Radar · NCT06347003

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 446 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

446

Actual

Start

Jul 22, 2024

Primary completion

Jun 12, 2026

Study completion Aug 25, 2026

Sponsor

Lead sponsor
Arrowhead PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Apr 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.

Conditions

  • Severe Hypertriglyceridemia

Interventions

  • Plozasiran InjectionDrug

    ARO-APOC3 Injection

  • PlaceboDrug

    sterile normal saline (0.9% NaCl)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Fasting Serum Triglyceride (TG) Levels from Baseline to Month 12 Compared to PlaceboTime frame: Baseline, Month 12

Locations

196 sites in 17 countries. Site status is shown where the registry gives one.

  • Research Center 1

    Garden Grove, California

  • Research Center 2

    Lake Forest, California

  • Research Center 3

    Montclair, California

  • Research Center 4

    Panorama City, California

  • Research Center 5

    Redding, California

  • Research Center 6

    Colorado Springs, Colorado

  • Research Center 7

    Hialeah, Florida

  • Research Center 8

    Lake City, Florida

  • Research Center 9

    Miami Lakes, Florida

  • Research Center 10

    Mt. Dora, Florida

  • Research Center 11

    Orlando, Florida

  • Research Center 12

    Pensacola, Florida

  • Research Center 13

    Tamarac, Florida

  • Research Center 14

    Tampa, Florida

  • Research Center 15

    Macon, Georgia

  • Research Center 16

    Savannah, Georgia

  • Research Center 17

    Park Ridge, Illinois

  • Research Center 18

    Eunice, Louisiana

  • Research Center 19

    Baltimore, Maryland

  • Research Center 20

    Flint, Michigan

  • Research Center 21

    Minneapolis, Minnesota

  • Research Center 22

    Olive Branch, Mississippi

  • Research Center 23

    Jefferson City, Missouri

  • Research Center 24

    St Louis, Missouri

  • Research Center 26

    Omaha, Nebraska

  • Research Center 25

    Omaha, Nebraska

  • Research Center 27

    Las Vegas, Nevada

  • Research Center 29

    Long Island City, New York

  • Research Center 30

    New York, New York

  • Research Center 31

    Rochester, New York

  • Research Center 28

    The Bronx, New York

  • Research Center 32

    Vestal, New York

  • Research Center 33

    Morehead City, North Carolina

  • Research Center 34

    Winston-Salem, North Carolina

  • Research Center 35

    Cincinnati, Ohio

  • Research Center 36

    Columbus, Ohio

  • Research Center 37

    Norman, Oklahoma

  • Research Center 38

    Oklahoma City, Oklahoma

  • Research Center 39

    Powell, Tennessee

  • Research Center 40

    El Paso, Texas

Showing 40 of 196 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.